Back to results
US 2026/0083689 A1Published application
Dextroamphetamine and lisdexamfetamine to reverse dexmedetomidine sedation
AssigneeThe General Hospital Corporation
InventorsKen Solt, Oluwaseun Johnson-Akeju, Emery N. Brown
Life of this patent
Estimating the term…
Abstract
Methods and compositions, e.g., compositions for intravenous administration, comprising dextroamphetamine and/or lisdexamfetamine for use in reversal of dexmedetomidine sedation.
Claims7
A pharmaceutical composition comprising dextroamphetamine, or a pharmaceutically acceptable salt thereof, and lisdexamfetamine, or a pharmaceutically acceptable salt thereof, optionally wherein the dextroamphetamine and lisdexamfetamine are present in a ratio of at least 1:1 up to 1:20, preferably 1:2 to 1:20, 1:5 to 1:20, or 1:8 to 1:12.
Dependencies are inferred from the claim text.